Procarbazine – Targeted Therapy

Procarbazine is an antineoplastic cytostatic agent belonging to the methylhydrazine derivative group. The drug is an alkylating agent with a unique multicomponent mechanism of action that effectively suppresses the replication of malignant cells. Procarbazine is classified as a cell cycle S-phase specific drug with the ability to cross the blood-brain barrier.

The mechanism of action of procarbazine is linked to its metabolic activation in the liver, during which active free radicals and methylating compounds are formed. These derivatives cause methylation of nucleic acids, leading to DNA strand breaks and inhibition of DNA, RNA, and protein synthesis. Additionally, the drug possesses the ability to inhibit the monoamine oxidase (MAO) enzyme, which accounts for its specific interactions with food products and other medications.

Due to its ability to effectively target central nervous system tissues and lymphoid tissue, procarbazine has become a key component of classic chemotherapy regimens, providing a significant increase in remission rates for lymphoproliferative diseases.

Wikipedia page
Procarbazine

Indications

Procarbazine is used as part of combination treatment regimens (such as MOPP or BEACOPP) for the following conditions:

  • Hodgkin's Lymphoma (Hodgkin's Disease): first-line and salvage therapy in combination with alkylating agents, vinca alkaloids, and glucocorticoids.
  • Non-Hodgkin Lymphomas: treatment of various histological types of malignant lymphomas resistant to standard therapy.
  • Brain Tumors: comprehensive therapy for malignant gliomas (including glioblastoma multiforme and anaplastic astrocytoma) in the PCV regimen.
  • Brill-Symmers Disease: (nodular lymphoma) in cases of progressive disease course.
  • Reticulosarcoma: as a component of palliative or radical chemotherapy.

Dosage and administration

The dosage of procarbazine is calculated individually by an oncologist, taking into account the protocol scheme and the patient's body surface area (BSA).

  • Standard Dose: typically ranges from 50–100 mg/m² of body surface area per day for 7–14 days within a single chemotherapy cycle.
  • Administration Method: the drug is taken orally. Tablets or capsules should be swallowed whole, preferably after meals, to reduce gastrointestinal irritation.
  • Dietary Restrictions: due to MAO inhibition, patients are strictly prohibited from consuming foods high in tyramine (aged cheeses, red wine, beer, smoked meats, chocolate) to avoid hypertensive crisis.
  • Alcohol: strictly contraindicated, as procarbazine causes a disulfiram-like reaction (nausea, vomiting, drop in blood pressure).
  • Therapy Monitoring: weekly monitoring of blood counts (leukocytes, platelets) and liver function is required. If the leukocyte count falls below 3000/µL, treatment is temporarily suspended.

The use of procarbazine is restricted in the presence of the following medical factors:

  • Hypersensitivity: known allergy to procarbazine or any of the excipients in the medication.
  • Severe Myelosuppression: baseline low levels of white blood cells or platelets in the peripheral blood.
  • Pregnancy and Lactation: the drug has potent teratogenic and mutagenic effects; breastfeeding during treatment is prohibited.
  • Severe Organ Impairment: pronounced renal or hepatic insufficiency.
  • Drug Interactions: simultaneous use of sympathomimetics, antidepressants (MAOIs or SSRIs), and ethanol.

Procarbazine can cause several serious adverse reactions requiring medical supervision:

  • Hematologic Toxicity: leukopenia, thrombocytopenia, and anemia (often delayed, peaking 2–4 weeks after administration).
  • Digestive System: severe nausea and vomiting (especially during the first days of intake), anorexia, and stomatitis.
  • Nervous System: paresthesia, neuropathy, increased somnolence, depression, or hallucinations.
  • Reproductive System: the drug often causes irreversible infertility (azoospermia in men) and amenorrhea in women.
  • Secondary Malignancies: increased risk of developing secondary acute leukemia several years after completion of treatment.

Frequently Asked Questions

Procarbazine is an antineoplastic agent belonging to the group of alkylating agents. It enters cancer cells and damages their DNA, preventing them from dividing and ultimately causing cell death. This substance can cross the blood-brain barrier, making it effective for treating certain brain tumors.
Procarbazine is primarily used to treat Hodgkin's lymphoma (typically as part of combination therapy like the BEACOPP regimen). The active substance is also effective against non-Hodgkin's lymphomas and certain malignant brain tumors, such as gliomas.
This is a critical safety requirement. Procarbazine acts as a weak monoamine oxidase inhibitor (MAOI). Consuming foods high in tyramine (such as aged cheeses, red wine, beer, smoked meats, and soy sauce) can cause a sudden and dangerous spike in blood pressure, known as a hypertensive crisis.
No, alcohol consumption is strictly prohibited. Procarbazine can cause a disulfiram-like reaction (similar to drugs used to treat alcoholism). Even small amounts of alcohol can trigger severe nausea, vomiting, facial flushing, headache, and a drop in blood pressure.
Procarbazine can cause bone marrow suppression, leading to a decrease in white blood cells (increased infection risk) and platelets (increased bleeding risk). These effects are often delayed and may appear several weeks after starting the cycle, making regular complete blood counts mandatory.

List of medicines by active substance

-10%
Hodpro 50 mg Neon
View
Neon

Hodpro

Procarbazine
50 mg 50 capsules
1992₴ 2213₴
✅ All products loaded (1)

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00